The objective of this project is to define the reaction mechanisms of human placental 3beta-hydroxysteroid dehydrogenase/steroid 5->4-ene- isomerase (3beta-HSD/isomerase) by relating function to structure. In placenta, 3beta-HSD/isomerase catalyzes the conversion of maternal pregnenolone to progesterone, a hormone that promotes uterine quiescence during pregnancy. The enzyme competitively utilizes dehydroepiandrosterone, the primary steroid product of the fetal adrenal gland near term, to produce androstenedione that is further metabolized to 17beta-estradiol. Thus, placental 3beta-HSD/isomerase bridges hormonal communication between the mother and fetus to mediate the locally increased estrogen/progesterone balance that has been associated with the onset of labor. Characterization of 3beta-HSD/isomerase may ultimately allow pharmacologic control of the placenta enzyme, independent of the different gonadal/adrenal isoenzyme, to prevent premature births. Homogeneous enzyme purified from human placenta is in-hand. Wild-type enzyme as been overexpressed by baculovirus in insect cells and found to be kinetically identical to native placenta enzyme. The order of substrate and coenzyme binding for the 3beta-HSD and isomerase activities is studied using both classic isotopic ligand exchange and novel affinity labeling/ligand protection experiments. The placenta isomerase reaction mechanism and activation by essential cofactor are compared to the known bacterial isomerase mechanism (with no cofactor requirement) by measuring spectral changes in 19-nortestosterone and 17beta-estradiol upon binding to the enzyme in the presence or absence of NADH. Stopped-flow spectroscopy experiments address our hypothesis that a time-dependent conformational change mediates the NADH-induced activation of isomerase. Affinity radiolabeling and ligand protection experiments map the binding sites for 3beta-HSD substrate, isomerase substrate, and cofactor in the known primary structure of this single, multifunctional protein. Using our cDNA that encodes placental 3beta-HSD/isomerase, probable catalytic amino acids in these identified regions are mutated using modified synthetic oligonucleotides. Probable cofactor and membrane anchoring regions are deleted. The mutated and wild-type cDNA are over-expressed by baculovirus in suspensions of insect Sf-9 cells. The functional significance of each expressed, purified mutant enzyme is determined by rigorous kinetic analyses previously applied to the native enzyme. These analyses include the measurement of Michaelis-Menton constants for 3beta- HSD substrates, isomerase substrates, and cofactors, inhibition kinetics for product steroids and NADH, and inactivation/protection profiles using affinity alkylators that are specific for the modified binding site. These structure/function studies localize the catalytic amino acids for the enzyme activities in the primary structure and test our unique hypothesis that the sequential 3beta-HSD and isomerase reactions are catalyzed at contiguous sites in a single steroid binding region.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD020055-12
Application #
2403131
Study Section
Biochemical Endocrinology Study Section (BCE)
Project Start
1985-08-01
Project End
1999-11-30
Budget Start
1997-12-01
Budget End
1999-11-30
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Washington University
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Thomas, James L; Duax, William L; Addlagatta, Anthony et al. (2004) Structure/function aspects of human 3beta-hydroxysteroid dehydrogenase. Mol Cell Endocrinol 215:73-82
Thomas, James L; Umland, Timothy C; Scaccia, Launa A et al. (2004) The higher affinity of human type 1 3beta-hydroxysteroid dehydrogenase (3beta-HSD1) for substrate and inhibitor steroids relative to human 3beta-HSD2 is validated in MCF-7 tumor cells and related to subunit interactions. Endocr Res 30:935-41
Thomas, James L; Duax, William L; Addlagatta, Anthony et al. (2003) Structure/function relationships responsible for coenzyme specificity and the isomerase activity of human type 1 3 beta-hydroxysteroid dehydrogenase/isomerase. J Biol Chem 278:35483-90
Thomas, James L; Mason, J Ian; Brandt, Stacey et al. (2002) Structure/function relationships responsible for the kinetic differences between human type 1 and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the type 1 activity. J Biol Chem 277:42795-801
Thomas, James L; Mason, J Ian; Brandt, Stacey et al. (2002) Differences in substrate and inhibitor kinetics of human type 1 and type 2 3beta-hydroxysteroid dehydrogenase are explained by the type 1 mutant, H156Y. Endocr Res 28:471-5
Thomas, J L; Mason, J I; Blanco, G et al. (2001) The engineered, cytosolic form of human type I 3beta-hydroxysteroid dehydrogenase/isomerase: purification, characterization and crystallization. J Mol Endocrinol 27:77-83
Thomas, J L; Evans, B W; Blanco, G et al. (1998) Site-directed mutagenesis identifies amino acid residues associated with the dehydrogenase and isomerase activities of human type I (placental) 3beta-hydroxysteroid dehydrogenase/isomerase. J Steroid Biochem Mol Biol 66:327-34
Mason, J I; Naville, D; Evans, B W et al. (1998) Functional activity of 3beta-hydroxysteroid dehydrogenase/isomerase. Endocr Res 24:549-57
Thomas, J L; Evans, B W; Strickler, R C (1997) Affinity radiolabeling identifies peptides associated with the isomerase activity of human type I (placental) 3beta-hydroxysteroid dehydrogenase/isomerase. Biochemistry 36:9029-34
Thomas, J L; Nash, W E; Strickler, R C (1996) Physiological 3 beta-hydroxy-5-ene steroid substrates bind to 3 beta-hydroxysteroid dehydrogenase without the prior binding of cofactor. J Steroid Biochem Mol Biol 58:211-6

Showing the most recent 10 out of 24 publications